Evicenter
P&T meetings

Atebrioz (zilurgisertib)

Fibrodysplasia ossificans progressiva

Also known as INCB000928
Regulatory submission
NDA submitted by May 2026
Last updated
96 sources

Product information and disease descriptionProduct descriptionProduct information

American hospital formulary service (AHFS), or other drug classification

1 evidence topic · 1 source

American Hospital Formulary Service classification and WHO Anatomical Therapeutic Chemical code

No evidence found.

Pharmacologic class stated in the prescribing information

“ATEBRIOZ is an activin receptor-like kinase-2 (ALK2) inhibitor indicated to reduce the volume of total new heterotopic ossification (HO) in adults and pediatric patients aged 12 years and older with fibrodysplasia ossificans progressiva (FOP).” (opens the prescribing information at this quote)